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A large number of human papillomavirus (HPV) types, distributed over five papillomavirus genera, are
detectable in the skin. HPV types belonging to the alpha, gamma, and mu genera have been detected in
cutaneous warts. A state-of-the-art HPV genotyping assay for these cutaneous wart-associated HPV types does
not exist although warts constitute a highly prevalent skin condition, especially in children (33%) and organ
transplant recipients (45%). Cutaneous warts are again the focus of attention as their clinical relevance rises
with the increasing number of chronically immunosuppressed patients. The objective of this study was to
develop and evaluate a DNA-based genotyping system for all known cutaneous wart-related HPV types using
PCR and Luminex xMAP technology. The broad-spectrum PCR amplified DNA of all known wart-associated
HPV types from the genera alpha (HPVs 2, 3, 7, 10, 27, 28, 29, 40, 43, 57, 77, 91, and 94), gamma (HPVs 4, 65,
95, 48, 50, 60, and 88), mu (HPVs 1 and 63), and nu (HPV41). The probes were evaluated using plasmid HPV
DNA and a panel of 45 previously characterized cutaneous wart biopsy specimens showing high specificity.
HPV was also identified in 96% of 100 swabs from nongenital cutaneous warts. HPV types 1, 2, 27, and 57 were
the most prevalent HPV types detected in 89% of the swabs. In conclusion, this Luminex-based genotyping
system identifies all known cutaneous wart HPV types including phylogenetically related types, is highly HPV
type specific, and is suitable for large-scale epidemiological studies.
Papillomaviruses (PV) constitute a group of viruses associ-
ated with benign and malignant proliferative lesions of cuta-
neous and mucosal epithelia. The taxonomic family of PV
includes 16 genera (5). More than 100 human papillomavirus
(HPV) types have been fully sequenced. The number of HPV
types that are not yet fully characterized is probably much
larger. HPV types, distributed over five genera (alpha, beta,
gamma, mu, and nu) and 16 species, infect the skin (5). HPV
types belonging to species of three genera (alpha, gamma, and
mu) have most frequently been detected in hyperkeratotic skin
lesions (warts).
The alphapapillomavirus (alpha-PV) types infecting the gen-
ital mucosa (e.g., HPV16, HPV18, HPV6, and HPV11) are the
best understood. HPV16 and HPV18 are the most prevalent
types involved in the pathogenesis of anogenital (e.g., cervical)
cancer, and HPV types 6 and 11 cause genital warts and laryn-
geal papillomas. The alpha-PV types belonging to species 2, 4,
and 8, which have been detected in cutaneous warts, have been
studied less thoroughly. At present the most frequently de-
tected alpha-PV types in cutaneous warts are HPV types 2, 3,
10, 27, and 57 (3, 10, 12–16, 18, 19). Gamma-PV types, includ-
ing HPV4, HPV60, and HPV65, have also regularly been de-
tected in cutaneous warts (4, 10, 12, 15). Mu-PV types, HPV1
and HPV63, have also been detected in cutaneous warts (7).
HPV types included in the beta and nu genera have rarely been
detected in cutaneous warts. Only Harwood and coworkers
(13) have described the presence of beta-PV types in cutane-
ous warts of immunosuppressed patients. The nu-PV genus
consists of only one HPV type (HPV41), which was originally
isolated from a facial wart (11).
In general, cutaneous warts from immunocompetent and
immunocompromised patients appear to show the same geno-
type distributions (16, 19). This has to be confirmed by a
large-scale study comparing the distributions in the two pop-
ulations with the same techniques. The number of detected
types per lesion appeared to differ between immunocompetent
and immunosuppressed patients (13). Currently, cutaneous
warts are again the focus of attention with the increasing num-
ber of chronically immunosuppressed patients (9, 20). Signifi-
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cant physical and psychological morbidity in these patients may
result from the existence of confluent plaques of warts present
on cosmetically sensitive areas such as the face and hands and
the presence of large warts occurring on pressure-bearing ar-
eas such as the feet.
Although cutaneous warts constitute a highly prevalent skin
condition, especially in children (33%) (22) and organ trans-
plant recipients (45%) (2), only a few large-scale epidemiolog-
ical studies including more than 100 lesions have investigated
the distribution of HPV types in cutaneous warts. These studies
utilized different detection methods, such as general primer-
mediated PCR followed by HPV typing with direct sequencing
(12, 15) or by restriction enzyme cleavage of the PCR product
(18). Other methods employed were multiple-type-specific
PCR combined with direct sequencing (3), in situ hybridization
(8), and (Southern) blot hybridization (6, 10). Although these
methods are in general type specific, they are time-consuming
and therefore less suitable for large scale-epidemiological
studies. In the case of multiple infections, reliable typing might
also be difficult with direct sequencing of the PCR amplimer
without prior molecular cloning. Therefore, we have evaluated
a novel broad-spectrum PCR–multiplex genotyping (MPG) as-
say called the hyperkeratotic skin lesion (HSL) PCR/MPG for
identification of established and candidate cutaneous wart
HPV types. These types are included in the alpha genus species
2 (HPVs 3, 10, 28, 29, 77, and 94), species 4 (HPVs 2, 27, and
57), and species 8 (HPVs 7, 40, 43, and 91); gamma genus
species 1 (HPVs 4, 65, and 95), species 2 (HPV48), species 3
(HPV50), species 4 (HPV60), and species 5 (HPV88); mu
genus species 1 (HPV1) and species 2 (HPV63); and nu genus
species 1 (HPV41). In this study the sensitivity, the HPV type
specificity, and the clinical performance of the HSL-PCR/
MPG broad-spectrum assay have been investigated.
MATERIALS AND METHODS
Clinical materials. Two panels of clinical samples were available. The first
panel consisted of purified DNA obtained from 45 nongenital cutaneous warts
that were taken from immunocompetent patients, immunosuppressed organ
transplant patients, and HIV-positive patients. These samples had been previ-
ously HPV genotyped by DNA sequencing using a purified PCR product from
two rounds of nested PCR utilizing the primer pair HVP2-B5 for the first round
and the pairs CN1F-CN1R, CN2F-CN2R, and CN3F-CN3R for the second
round (sequencing) or the single-round primer pair C4F-C4R (PCR and se-
quencing), as described by Harwood and coworkers (13). The use of separate
reaction mixtures with different primer pairs allowed the identification of mul-
tiple HPV types. In some cases DNA sequencing was not carried out with all of
the primer pairs (Table 1).
A second panel comprised swabs taken from 100 cutaneous warts derived from
100 individuals (age of 4 years) with one or more cutaneous warts who self-
presented to their general practitioners. The warts were present mainly on hands
and feet. The swabs were taken from one wart from each patient by firmly
rubbing a prewetted cotton-tipped stick five times over the surface of the lesion.
Next, the swabs were put in 1 ml of saline solution, and 10 l was used directly
in the novel HSL-PCR/MPG assay.
Plasmids. For the evaluation of the analytical type specificity of the HSL-PCR/
MPG assay (Labo Biomedical Products BV, Rijswijk, Netherlands), amplimers
were generated using plasmid clones containing sequences of the following types:
HPV types 1, 2, 3, 4, 7, 10, 27, 28, 29, 40, 41, 43, 48, 50, 57, 60, 63, 65, 77, 88, 91,
94, and 95. Plasmids containing HPV genomic DNA were kindly provided by
E.-M. de Villiers (HPVs 1, 4, 7, 41, 48, and 63), O. Forslund (HPV88), M. Favre
(HPV10), T. Matsukura (HPV60), R. Ostrow (HPV3), G. Orth (HPVs 28, 29,
and 50), and A. Lorincz (HPV43). For HPV types 2, 27, 40, 57, 65, 77, 91, 94, and
95, the relevant HPV sequence was synthesized, cloned, and sequenced (Gen-
Script USA, Inc.). In order to confirm amplification of an HPV-specific frag-
ment, gel electrophoresis was performed with 2.2% FlashGel agarose gels
(Lonza, Basel, Switzerland). To determine the analytical sensitivity of the assay,
DNA concentrations of the plasmids were determined using a NanoDrop 2000
instrument (Thermo Fisher Scientific Inc.), and 10-fold serial dilutions were
made in a background of 12 ng/l human genomic DNA. This background
human DNA is equivalent to approximately 24,000 cells per 10 l of plasmid
sample.
TABLE 1. Comparison of HSL-PCR/MPG assay results with
direct DNA sequencing on PCR amplimers obtained from
purified DNA from 45 warts
Sample
no.
HPV type(s) by: Comparison of
resultsfHSL-PCR/MPG DNA sequencing
1 27 27 I
2 27 27 I
3 27 27, 94 C
4 27 27, 94 C
5 27 27 I
6 28 28 I
7 27 27 I
8 2 2 I
9 Negative Negative I
10 27 27 I
11 (3)a, 7 3 C
12 (3)a, 7 3 C
13 27 27 I
14 2 2 I
15 57 57 I
16 57 57 I
17 57 28, 57 C
18 57 57 I
19 57 57 I
20b 57 72 D
21b Negative 72 I
22c 4 27, 28 D
23 27 27, 28 C
24 57 57 I
25 27 27 I
26 27 27 I
27 27, 57, 95 27 C
28 27, 57 27 C
29 57 57 I
30 57 57 I
31 1, 3, 57 3 C
32 3, 57 57 C
33 57 57 I
34 4 4 I
35 2 2 I
36 2 2 I
37d 7 10 D
38 4, 7, 10 7, 10, 27 C
39 4, 7, 10 7, 10, 27 C
40 7 7, 10 C
41 7, 10 10, 27 C
42 10, 27 27 C
43e 63 27 D
44 27 27 I
45 4 4 I
a Elevated signal but below cutoff for HPV3 with the HSL-PCR/MPG. There
was no sequencing result for HPV7; HPV7 was confirmed by a third assay.
b HPV72 not included in the HSL-PCR/MPG assay.
c No sequencing result for HPV4 available.
d Repeated DNA sequencing negative.
e Repeated DNA sequencing did not confirm HPV27.
f I, both methods yielded completely identical genotyping results (concordant);
C, both methods showed one or more of the same genotype(s) (compatible); D,
no similarity between genotypes detected by both methods (discordant).
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HSL-PCR/MPG assay. The HSL-PCR/MPG assay comprises the HSL-PCR
generating a biotinylated amplimer of 76 to 84 bp from the L1 region and a
genotyping assay with bead-based xMAP suspension array technology, which is
able to simultaneously identify 23 HPV genotypes. Within the L1 gene of HPV
a region suitable for broad-spectrum PCR and genotyping was used (Fig. 1). The
primer set consisted of 27 nondegenerate primers (13 forward and 14 reverse)
without inosines. All PCRs were carried out with all precautions to avoid con-
tamination, as described by the manufacturer (Labo Biomedical Products BV,
Rijswijk, Netherlands).
Briefly, HSL-PCR was performed in a final reaction volume of 50 l, contain-
ing 10 l of the isolated DNA, 2.0 mM MgCl2, 1 GeneAmp PCR Buffer II, 0.2
mM deoxynucleoside triphosphates (dNTPs), 1.5 U of AmpliTaq Gold DNA
polymerase, and 10 l of the primer mix. The PCR was performed by a 9-min
preheating step at 94°C, followed by 35 cycles of amplification comprising 30 s at
94°C, 45 s at 55°C, and 45 s at 72°C. A final elongation step at 72°C for 5 min
ended the PCR.
The HSL-PCR/MPG assay permitted the simultaneous identification of mul-
tiple HPV genotypes in a single hybridization step. Twenty-four genotyping
probes were selected from the PCR target region (Fig. 1) and were immobilized
on color-coded beads. Since the HPV genotypes included in the assay often differ
by only a few nucleotides in the probe region, well-controlled assay conditions
and probe selection were required. The HSL-PCR/MPG assay was performed
according to the manufacturer’s instructions in a Luminex 100 IS System (Lu-
minex Corporation, Austin, TX) that was calibrated weekly. Briefly, 3B buffer
was added to the provided bead mix to minimize background in the final Lumi-
nex readout. Subsequently, HSL-PCR products were added. Next, heat denatur-
ation, hybridization under stringent conditions, and incubation with streptavidin-
conjugated R-phycoerythrin detection conjugate, followed by readout according
to the specified instrument settings, resulted in median fluorescence intensity
(MFI) levels per HPV type for each specimen. No distinction was made between
samples positive for HPV type 2 variant (HPV2var) and HPV2 as they are both
scored as HPV2 positive.
Sequence analysis. For sequence analysis of the HSL amplimers from the
plasmid clones generated with use of type-specific primers, amplimers were
treated with ExoSAP-IT (USB, OH) to remove unconsumed dNTPs and prim-
ers. Purified amplimers were directly sequenced according to the manual of the
Big Dye Terminator Cycle Sequencing kit using forward and reverse HSL-PCR
primers. The sequence products were subsequently read using a 3100-Avant
Genetic Analyzer. The resulting DNA sequences were analyzed with Vector NTI
Advance, version 9.0, software and compared with all known HPV types present
in the National Center for Biotechnology Information (NCBI) database utilizing
nucleotide-nucleotide BLAST (BLASTN) searches (1) (http://www.ncbi.nlm.nih
.gov/BLAST/).
HPV sequences from GenBank. The following are accession numbers of HPV
sequences obtained from GenBank (http://www.ncbi.nlm.nih.gov/GenBank
/index.html) and used as references for the corresponding HPV genotypes: HPV
type 3, X74462; HPV type 10, X74465; HPV type 28, U31783; HPV type 29,
U31784; HPV type 77, Y15175; HPV type 94, AJ620211; HPV2var, DQ080000;
HPV type 2, X55964; HPV type 27, X73373; HPV type 57, X55965; HPV type 7,
X74463; HPV type 40, X74478; HPV type 43, AJ620205; HPV type 91,
AF419318; HPV type 4, X70827; HPV type 48, U31789; HPV type 50, U31790;
HPV type 60, U31792; HPV type 65, X70829; HPV type 88, EF467176; HPV
type 95, AJ620210; HPV type 1, V01116; HPV type 63, X70828; HPV type 41,
X56147.
RESULTS
Analytical type specificity of the HSL-PCR/MPG. DNA
from 24 plasmids containing partial or complete HPV genomic
sequences representing established types from alpha-, gamma-,
mu-, and nu-PV genera was analyzed by HSL-PCR/MPG. Am-
plimers were identified on agarose gels, and a fragment of the
expected size (76 to 84 bp) was present (data not shown).
Subsequent sequence analysis (data not shown) confirmed that
the correct genotypes were amplified. For all HPV sequences
the genotyping assay showed type-specific hybridization, with
MFI values ranging from 2,133 to 7,667 for targeted HPV types
(Fig. 2).
Analytical sensitivity of the HSL-PCR/MPG. Sensitivity tests
were performed on 10-fold serial dilutions of plasmid clones of
HPV types 1, 2, 3, 4, 7, 10, 27, 28, 29, 40, 41, 43, 48, 50, 57, 60,
63, 65, 77, 88, 91, 94, and 95 made in a background of 12 ng/l
human DNA. The analytical sensitivity of the HSL-PCR/MPG
assay ranged from 1 to 10 copies per PCR for HPV types 1 and
2; from 10 to 100 copies per PCR for HPV types 2 variant, 4,
7, 10, 43, 48, 63, and 95; from 100 to 1,000 copies per PCR for
HPV types 3, 27, 29, 57, 60, 65, and 77; and from 1,000 to
10,000 copies per PCR for HPV types 28, 40, 41, 50, 88, 91, and
94 (data not shown).
FIG. 1. Nucleotide sequence alignment of the target region for the HSL-PCR for 23 HPV types. The nucleotides identical to the top sequence
(HPV3) are indicated as dots. Within the alpha genus the HPV types are ordered per species, with species 2 consisting of HPV types 3, 10, 28,
29, 77, and 94; species 4 consisting of HPV types 2, 2 variant, 27, and 57; and species 8 consisting of HPV types 7, 40, 43, and 91.
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Clinical performance of the HSL-PCR/MPG. The HSL-
PCR/MPG yielded an HPV genotyping result identical to that
of sequencing in 26 of the 45 nongenital cutaneous wart DNA
samples derived from immunocompetent patients, immuno-
suppressed organ transplant patients, and HIV-positive pa-
tients. In 15 of 45 cases the result was compatible (i.e., an
additional HPV type was detected by either method [21]) (Ta-
ble 1). In four of 45 cases the results were discordant. In two of
these four cases the result with one or both assays was positive
for an HPV type that was not included in the other assay, and
these two samples were excluded. Two other discordant results
remain unresolved since repeated sequencing did not confirm
the first result.
Second, the performance of the HSL-PCR/MPG assay was
evaluated on cutaneous wart swabs. The positivity rate was
96% in swabs taken from nongenital cutaneous warts mainly
present on hands and feet of 100 patients (see Materials and
Methods). The most prevalent HPV types were HPV1 (genus
mu species 1) and HPVs 2, 27, and 57 (genus alpha species 4).
Together, these HPV types were detected in 89% of the cuta-
neous wart swabs. Other HPV types detected were HPVs 3, 4,
7, 63, 65, and 95 (Table 2). In one case the generated amplimer
of the expected size, as visualized by agarose gel electrophore-
sis, did not hybridize with the available genotyping probes. In
three other cases the HSL-PCR/MPG did not generate an
amplimer of the expected size and did not give a positive signal
with the genotyping assay. Within these 100 samples, 11 mul-
tiple infections were observed; of these 10 contained two HPV
types and 1 was positive for three types.
DISCUSSION
In this study, we have described the evaluation of a novel,
sensitive, single-step broad-spectrum PCR targeting the HPV
L1 region combined with a Luminex-based hybridization assay
for the detection and genotyping of HPV types associated with
nongenital cutaneous warts. The HSL-PCR was able to amplify
FIG. 2. Analytical type specificity of the HSL-PCR/MPG. Indicated are the MFI readouts (without background subtraction) of HSL-PCR
amplimers generated from 6  108 to 7  107 copies of different HPV plasmids (listed on top) in relation to the bead-bound capture probes (listed
on the left). The conjugate control (conj) serves as the positive control for correct incubation with the detection conjugate for each separate
specimen. HPV2 and HPV2var (2v) are both scored as HPV2 positive.
TABLE 2. HPV type distribution in 100 swabs taken
from a single wart of 100 persons
Genus Species no. Genotype % Positivitya





Gamma 1 HPV4 5
HPV65 1
HPV95 1
Mu 1 HPV1 31
2 HPV63b 1
a Eleven samples showed multiple infections; 10 of these samples were positive
for two types and 1 was positive for three types. Four samples were negative with
the genotyping assay.
b Only detected once in a multiple infection with HPV1.
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HPV DNA from various sources and showed an analytical
sensitivity of 1 to 10,000 HPV copies per PCR in a human
genomic DNA background. The analytical HPV type specific-
ity was 100%, as shown by analyzing amplimers generated from
all 23 included HPV types at a concentration ranging from 6 
108 to 7  107 viral genome copies per PCR. When the novel
HSL-PCR/MPG method was compared with an established
DNA sequencing method (13) targeting a different part of the
L1 open reading frame, the results were highly concordant.
Forty-one of the 43 included samples gave identical or com-
patible results (95%), and two gave discordant results, con-
firming the high analytical specificity of the novel genotyping
method.
The reproducibility of the Luminex system which was used
for the HSL-PCR/MPG assay has been extensively investigated
by an analogue, broad-spectrum PCR genotyping assay
(Digene HPV Genotyping LQ Test package insert) and was
higher than 95%.
The median MFI values, representing the general back-
ground signals in all 130 analyzed clinical samples consisting of
swabs and biopsy specimens, were very low, ranging from 1 to
9 MFI for the different probes. The observed cross-reactions in
clinical samples were all confirmed by experiments with plas-
mid dilutions using an input of up to 108 viral genome copies
per PCR. Furthermore, DNA sequence alignments between
the probes and cross-hybridizing HPV types (data not shown)
indicated that a small number of mismatches explained the
cross-hybridization reactions with a maximum signal of 131
MFI. Whereas the general background signals were between 1
and 9 MFI, theoretically allowing for a low cutoff, the detected
cross-hybridization reactions with some probes resulted in the
use of a conventional cutoff of 200 MFI for all types. Using this
high cutoff for all HPV types included in the assay could cause
an underestimation of the prevalence of certain HPV types.
Amplimers of HPV27 gave cross-hybridization reactions
with the probe for HPV2var that resulted in MFI signals higher
than 200 MFI. The highest observed cross-reactive signal was
detected in purified DNA from a cutaneous wart positive for
HPV27, with an MFI value of 9,226. The cross-reactive signal
for HPV2var was 534 MFI in this case. Therefore, the cutoff
for HPV2var positivity was set at 700 MFI in multiple infec-
tions with HPV27 signals above 7,500 MFI.
Similarly, amplimers of HPV10 and HPV28 gave cross-hy-
bridization reactions with the probe for HPV94 that resulted in
MFI signals higher than 200 MFI, with a maximum of 221 MFI.
Consequently, we used a cutoff for HPV94 positivity of 500
MFI in a multiple infection with HPV10 or HPV28 when these
types had higher signals than 4,000 or 1,500 MFI, respectively.
In the absence of these types, the assay’s conventional cutoff
of 200 MFI was used. This cutoff value is well above the
background signals and was chosen as a precaution because
cutaneous warts could produce very high concentrations of
viral DNA, possibly challenging the specificity of the genotyp-
ing system. The downside of this precaution is reflected by the
analytical sensitivity of the assay, which ranges from 1 to 10,000
copies per PCR. However, in the panel of 100 swabs of cuta-
neous warts, 96 (96%) of the samples were HPV positive,
indicating a high enough analytical sensitivity of the assay for
this kind of sample.
Current methods for the determination the HPV genotypes
in cutaneous warts are generally based on Southern blot hy-
bridization or on general primer-mediated PCR or type-spe-
cific PCR followed by direct DNA sequencing. Although these
methods can provide accurate results, they are laborious and
not suitable for use in large epidemiological studies. The assay
format of the novel HSL-PCR/MPG method encompasses a
broad-spectrum PCR amplifying all known cutaneous wart-
associated HPV types, followed by a multiplex genotyping as-
say in a high-throughput setting, which allowed genotyping of
a panel of PCR products derived from 96 samples in about 2 h.
The HSL-PCR was designed to amplify all HPV types pre-
viously found in cutaneous warts as well as related types from
the same species (5). Complementing established types with
the HPV types present in the same species is based on the
assumption that these types might also be involved in cutane-
ous wart etiology analogous to the cervical cancer risk associ-
ated with not only HPV16 but also other types included in the
same alpha-PV species 9. In this study swabs from 100 cuta-
neous warts were analyzed from individuals attending their
general practitioners for treatment. Therefore, this panel was
probably representative for warts in the general (Dutch) pop-
ulation. We confirmed the presence of similar HPV types as
reported in the literature, but the other types present in the
same HPV species were not often detected in this panel.
Whether these other types occur less frequently or only in
specific patient groups (e.g., HIV-infected persons) will be the
subject of further investigations.
The common and easily accessible nature of cutaneous warts
led early on to prolific clinical research in PV (17). Currently,
these skin lesions are again the focus of attention as the clinical
relevance of cutaneous warts rises with the increasing number
of chronically immunosuppressed patients (9, 20). Significant
physical and psychological morbidity in these patients may
result from the existence of confluent plaques of warts present
on cosmetically sensitive areas such as the face and hands and
the presence of large warts occurring on pressure-bearing ar-
eas such as the feet. The impact of these problems and the
difficulty in treating them should not be underestimated. In-
deed, in some cases they may prompt the use of lower levels of
immunosuppression, thus potentially endangering graft sur-
vival. In addition, the recently available preventive vaccines for
HPV types causing cervical cancer pave the way for preventive
and possibly therapeutic vaccines against cutaneous warts, par-
ticularly in the case of organ transplant recipients and patients
with HIV. The development of these vaccines will, however,
require a greater understanding of the HPV types that cause
cutaneous warts and their natural history. Easy-to-use, high-
throughput genotyping systems such as that described in this
study will be invaluable for this future research.
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